By Yantoultra Ngui SINGAPORE, July 13 (Reuters) – Mylan Inc, part of a global healthcare company Viatris, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters. • The sale represents up to 5.64% of […]
Health
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows
Audio By Carbonatix
By Yantoultra Ngui
SINGAPORE, July 13 (Reuters) – Mylan Inc, part of a global healthcare company Viatris, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.
• The sale represents up to 5.64% of Biocon’s outstanding shares. It is a secondary sale, meaning the shares are being sold by an existing investor and Biocon will not receive the proceeds.
• The offer floor price is 378.50 rupees per share, a 7.9% discount to Biocon’s last close of 410.95 rupees on Monday.
• Biocon did not immediately respond to an emailed request seeking comment.
• “We do not comment on market rumors or speculation,” Viatris said in response to a Reuters request for comment.
• Citigroup Global Markets India and Jefferies India are joint bookrunners and brokers for the deal.
($1 = 95.6200 Indian rupees)
(Reporting by Yantoultra NguiEditing by Tomasz Janowski)